No trading implications from this filing, it reflects a routine governance adjustment with no change in board composition or leadership. Monitor upcoming proxy filings for any additional board changes or governance updates.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 24 $3.29entry
- T+1 · 7mo ago −0.91%α −1.08% · $3.26
- T+5 · 7mo ago 0.00%α −0.91% · $3.29
- T+20 · 6mo ago −4.26%α −8.28% · $3.15
- T+60 · 4mo ago −3.95%α −9.03% · $3.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sana Biotechnology reclassified director Steven D. Harr, M.D. from a Class I to a Class III director to balance board class composition in accordance with its charter. The move was administrative, with no interruption in service, and the board now has three directors in each class.
Key Facts
- Steven D. Harr, M.D. resigned as a Class I director and was immediately reappointed as a Class III director.
- The reclassification was made to achieve equal balance among the three board classes per the company's Certificate of Incorporation.
- Dr. Harr's board service is deemed to have continued uninterrupted.
- The board now consists of three directors in each of Class I, II, and III.
Financial Impact
No financial impact, this was an administrative board reclassification.
Risk Factors
- None identified, this was a procedural board rebalancing with no executive departure or governance controversy.
- Minimal investor relations risk given the clear explanation and continuity of service.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-174531 |
| Document: 0001193125-26-174531-index-headers.html | 0001193125-26-174531 |
| Document: 0001193125-26-174531-index.html | 0001193125-26-174531 |
| Document: 0001193125-26-174531.txt | 0001193125-26-174531 |
Track record
12 reports on SANA
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +13.50% at T+20 after the May 11, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $2.37 Now $1.88 −20.68% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $2.34 Now $1.88 −19.66% settles Dec 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $3.79 to $3.17 Now $1.88 −50.40% ▼ −16.36% −15.30% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $3.26 to $2.82 Now $1.88 +42.33% ▲ +13.50% +11.77% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 4/10 Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 24, 202629w ago 8-K Neutral 2/10 Viewing Entry $3.29 to $3.15 Now $1.88 −42.86% ▼ −4.26% −8.28% vs SPY
- Apr 13, 202631w ago 8-K Bullish 6/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
- Apr 13, 202631w ago Press Release Bullish 7/10 Entry $3.48 to $3.56 Now $1.88 −45.98% ▲ +2.30% −4.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers